Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -41.80% is in line with its 5-year average of -40.11%, around the middle of its 5-year range (-76.23%–-15.92%).
As of the fiscal period ended Tuesday, June 30, 2026. 2.21% below its 12-month average of -40.89%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -41.80%.
RETURN ON INVESTED CAPITAL (ROIC)
-41.80%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-40.89%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-42.33%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-40.11%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
-2.21%
CURRENT VS 3Y AVG
+1.26%
CURRENT VS 5Y AVG
-4.21%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-33.19%
median of 716 covered companies
CURRENT VS SECTOR MEDIAN
-25.96%
vs the sector median at left
NEXGEL, Inc.
Market Cap
$1.41M
Return on Invested Capital (ROIC)
-41.80%
TTM Avg
-40.89%
3Y Avg
-42.33%
5Y Avg
-40.11%
Market Cap
$1.41M
Return on Invested Capital (ROIC)
-219.36%
TTM Avg
-214.97%
3Y Avg
-160.97%
5Y Avg
-133.06%
Market Cap
$1.42M
Return on Invested Capital (ROIC)
-28.43%
TTM Avg
-37.81%
3Y Avg
-267.17%
5Y Avg
-197.37%
Market Cap
$1.46M
Return on Invested Capital (ROIC)
-163.98%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.35M
Return on Invested Capital (ROIC)
-107.08%
TTM Avg
-750.62%
3Y Avg
-506.81%
5Y Avg
-355.90%
Market Cap
$1.50M
Return on Invested Capital (ROIC)
N/A
TTM Avg
-48.91%
3Y Avg
-66.07%
5Y Avg
-87.70%
Market Cap
$1.48M
Return on Invested Capital (ROIC)
-567.17%
TTM Avg
-332.51%
3Y Avg
-201.53%
5Y Avg
-141.19%
Market Cap
$1.33M
Return on Invested Capital (ROIC)
-32.53%
TTM Avg
-171.99%
3Y Avg
-201.88%
5Y Avg
-239.63%
Market Cap
$1.24M
Return on Invested Capital (ROIC)
-709.40%
TTM Avg
-164.13%
3Y Avg
-164.13%
5Y Avg
-164.13%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NEXGEL, Inc. (NXGL) | $1.41M | -41.80% | -40.89% | -42.33% | -40.11% |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.41M | -219.36% | -214.97% | -160.97% | -133.06% |
| INVO Fertility, Inc. (IVF)vs › | $1.42M | -28.43% | -37.81% | -267.17% | -197.37% |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.46M | -163.98% | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.35M | -107.08% | -750.62% | -506.81% | -355.90% |
| PMGC Holdings Inc. (ELAB)vs › | $1.50M | N/A | -48.91% | -66.07% | -87.70% |
| Curis, Inc. (CRIS)vs › | $1.48M | -567.17% | -332.51% | -201.53% | -141.19% |
| NewcelX Ltd. (NCEL)vs › | $1.33M | -32.53% | -171.99% | -201.88% | -239.63% |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.24M | -709.40% | -164.13% | -164.13% | -164.13% |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.18M | -183.49% | -279.63% | -279.63% | -279.63% |
ROIC
-41.8%
ROE
-125.0%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -41.80% |
| 2026-03-31 | -42.14% |
| 2025-12-31 | -44.08% |
| 2025-09-30 | -35.42% |
| 2025-06-30 | -41.03% |
| 2025-03-31 | -43.16% |
| 2024-12-31 | -41.28% |
| 2024-09-30 | -49.45% |
| 2024-06-30 | -51.95% |
| 2024-03-31 | -43.36% |
| 2023-12-31 | -44.96% |
| 2023-09-30 | -36.18% |
| 2023-06-30 | -39.17% |
| 2023-03-31 | -35.14% |
| 2022-12-31 | -35.19% |
| 2022-09-30 | -33.40% |
| 2022-06-30 | -24.14% |
| 2022-03-31 | -21.71% |
| 2021-12-31 | -15.92% |
| 2021-09-30 | -61.62% |
| 2021-06-30 | -76.23% |
| 2021-03-31 | -103.18% |
| 2020-12-31 | -198.07% |
| 2020-09-30 | -134.35% |
| 2020-06-30 | -85.70% |
| 2020-03-31 | -146.97% |
| 2019-12-31 | -176.51% |
| 2019-09-30 | -234.20% |
| 2019-06-30 | -421.41% |
| 2019-03-31 | -179.93% |
| 2018-12-31 | -591.27% |
| 2018-09-30 | -271.62% |
